(2022). . , 77(6), 2235-2242. doi: 10.22092/ari.2022.358489.2230
. "". , 77, 6, 2022, 2235-2242. doi: 10.22092/ari.2022.358489.2230
(2022). '', , 77(6), pp. 2235-2242. doi: 10.22092/ari.2022.358489.2230
. , 2022; 77(6): 2235-2242. doi: 10.22092/ari.2022.358489.2230

Archives of Razi Institute
Article 27, Volume 77, Issue 6, January and February 0, Pages 2235-2242    PDF (728.05 K)
Document Type: مقالات پژوهشی
DOI: 10.22092/ari.2022.358489.2230
Supplementary Files
References
  1. Adamus-Bialek W, Zajac E, Parniewski P, Kaca W. Comparison of antibiotic resistance patterns in collections of Escherichia coli and Proteus mirabilis uropathogenic strains. Mol Biol Rep. 2013;40(4):3429-35.
  2. Schaffer JN, Pearson MM. Proteus mirabilis and Urinary Tract Infections. Microbiol Spectr. 2015;3(5).
  3. Slattery S, Tony Pembroke J, Murnane JG, Ryan MP. Isolation, nucleotide sequencing and genomic comparison of a Novel SXT/R391 ICE mobile genetic element isolated from a municipal wastewater environment. Sci Rep. 2020;10(1):8716.
  1. Bitar I, Mattioni Marchetti V, Mercato A, Nucleo E, Anesi A, Bracco S, et al. Complete Genome and Plasmids Sequences of a Clinical Proteus mirabilis Isolate Producing Plasmid Mediated NDM-1 from Italy. Microorganisms. 2020;8(3).
  2. Mac Aogain M, Rogers TR, Crowley B. Identification of emergent bla CMY-2 -carrying Proteus mirabilis lineages by whole-genome sequencing. New Microbes New Infect. 2016;9:58-62.
  3. Sun L, Xu J, He F. Genomic characterisation of a Proteus mirabilis clinical isolate from China carrying blaNDM-5 on an IncX3 plasmid. J Glob Antimicrob Resist. 2019;19:317-9.
  4. Kanzari L, Ferjani S, Saidani M, Hamzaoui Z, Jendoubi A, Harbaoui S, et al. First report of extensively-drug-resistant Proteus mirabilis isolate carrying plasmid-mediated blaNDM-1 in a Tunisian intensive care unit. Int J Antimicrob Agents. 2018;52(6):906-9.
  5. Firmo EF, Beltrao EMB, Silva F, Alves LC, Brayner FA, Veras DL, et al. Association of blaNDM-1 with blaKPC-2 and aminoglycoside-modifying enzyme genes among Klebsiella pneumoniae, Proteus mirabilis and Serratia marcescens clinical isolates in Brazil. J Glob Antimicrob Resist. 2020;21:255-61.
  6. Valentin T, Feierl G, Masoud-Landgraf L, Kohek P, Luxner J, Zarfel G. Proteus mirabilis harboring carbapenemase NDM-5 and ESBL VEB-6 detected in Austria. Diagn Microbiol Infect Dis. 2018;91(3):284-6.
  7. CLSI. Performance standard for antimicrobial susceptibility testing, Twenty-Fourth Informational Supplement: Clinical and Laboratory Standards Institute. 2019.
  8. Kim HB, Park CH, Kim CJ, Kim EC, Jacoby GA, Hooper DC. Prevalence of plasmid-mediated quinolone resistance determinants over a 9-year period. Antimicrob Agents Chemother. 2009;53(2):639-45.
  9. Belaaouaj A, Lapoumeroulie C, Canica MM, Vedel G, Nevot P, Krishnamoorthy R, et al. Nucleotide sequences of the genes coding for the TEM-like beta-lactamases IRT-1 and IRT-2 (formerly called TRI-1 and TRI-2). FEMS Microbiol Lett. 1994;120(1-2):75-80.
  10. Dillon B, Thomas L, Mohmand G, Zelynski A, Iredell J. Multiplex PCR for screening of integrons in bacterial lysates. J Microbiol Methods. 2005;62(2):221-32.
  11. Coker C, Poore CA, Li X, Mobley HLT. Pathogenesis of Proteus mirabilisurinary tract infection. Microbes Infect. 2000;2(12):1497-505.
  12. O'Hara CM, Brenner FW, Miller JM. Classification, identification, and clinical significance of Proteus, Providencia, and Morganella. Clin Microbiol Rev. 2000;13(4):534-46.
  13. Chikere C, Omoni V, Chikere B. Distribution of Potential Nosocomial Pathogens in an Hospital Environment. Afr J Biotechnol. 2008;7:3535-9.
  14. Okesola AO, Makanjuola O. Resistance to Third-Generation Cephalosporins and Other Antibiotics by Enterobacteriaceae in Western Nigeria. Am J Infect Dis. 2009;5(1).
  15. Soge OO, Adeniyi BA, Roberts MC. New antibiotic resistance genes associated with CTX-M plasmids from uropathogenic Nigerian Klebsiella pneumoniae. J Antimicrob Chemother. 2006;58(5):1048-53.
  16. Ogbolu DO, Daini OA, Ogunledun A, Alli AO, Webber MA. High levels of multidrug resistance in clinical isolates of Gram-negative pathogens from Nigeria. Int J Antimicrob Agents. 2011;37(1):62-6.
  17. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005;18(4):657-86.
  18. Canton R, Gonzalez-Alba JM, Galan JC. CTX-M Enzymes: Origin and Diffusion. Front Microbiol. 2012;3:110.
  19. Tijjani J, Arzai A, Sadiq N. Antimicrobial susceptibility pattern of extended-spectrum beta-lactamase producers in Gram negative urogenital isolates in Kano, Nigeria. Bayero J Pure Appl Sci. 2012;5:20-5.
  20. EnabuleleI O, YahS C, YusufE. O, EghafonaN. O, editors. Emerging quinolones resistant transfer genes among gram-negative bacteria, isolated from faeces of HIV/AIDS patients attending some Clinics and Hospitals in the City of Benin, Edo State, Nigeria. 2006.
  21. Martínez-Martínez L, Pascual A, Jacoby GA. Quinolone resistance from a transferable plasmid. Lancet (London, England). 1998;351(9105):797-9.
  22. Chen X, Zhang W, Pan W, Yin J, Pan Z, Gao S, et al. Prevalence of qnr, aac(6')-Ib-cr, qepA, and oqxAB in Escherichia coli isolates from humans, animals, and the environment. Antimicrob Agents Chemother. 2012;56(6):3423-7.
  1. Tran JH, Jacoby GA. Mechanism of plasmid-mediated quinolone resistance. Proc Natl Acad Sci U S A. 2002;99(8):5638-42.
  2. Tran JH, Jacoby GA, Hooper DC. Interaction of the plasmid-encoded quinolone resistance protein Qnr with Escherichia coli DNA gyrase. Antimicrob Agents Chemother. 2005;49(1):118-25.
  3. Jacoby GA. Mechanisms of resistance to quinolones. Clin Infect Dis. 2005;41 Suppl 2:S120-6.
  4. Robicsek A, Jacoby GA, Hooper DC. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis. 2006;6(10):629-40.
  5. Olowe O, Oladipo G, Makanjuola O, Olaitan J. Prevalence of extended-spectrum beta-lactamases (ESBLs)carrying genes in Klebsiella spp. from clinical samples at Ile-Ife, South Western Nigeria. Int J Pharma Med Biol Sci. 2012;1:2278-5221.
  6. Perichon B, Courvalin P, Galimand M. Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli. Antimicrob Agents Chemother. 2007;51(7):2464-9.
  7. Yamane K, Wachino J, Suzuki S, Kimura K, Shibata N, Kato H, et al. New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate. Antimicrob Agents Chemother. 2007;51(9):3354-60.
  8. Boucher Y, Labbate M, Koenig JE, Stokes HW. Integrons: mobilizable platforms that promote genetic diversity in bacteria. Trends Microbiol. 2007;15(7):301-9.
  9. Song W, Kim J, Bae IK, Jeong SH, Seo YH, Shin JH, et al. Chromosome-encoded AmpC and CTX-M extended-spectrum beta-lactamases in clinical isolates of Proteus mirabilis from Korea. Antimicrob Agents Chemother. 2011;55(4):1414-9.
  10. Alabi OS, Mendonca N, Adeleke OE, da Silva GJ. Molecular screening of antibiotic-resistant determinants among multidrug-resistant clinical isolates of Proteus mirabilis from SouthWest Nigeria. Afr Health Sci. 2017;17(2):356-65.
Statistics
Article View: 15,530
PDF Download: 57,342


counter
Journal management system. designed by sinaweb